Nicolas Favre
InvestorChief Business Officer, Business Development & Commercial at Debiopharm Innovation Fund
London, England, United Kingdom
About
Chief Business Officer overseeing Commercial and Business Development. He joined Debiopharm in 2016 and previously held R&D and marketing roles at Merck Serono, Lundbeck and Novo Nordisk. He holds a PhD from the University of Geneva and an MBA.
Experience
- DebiopharmChief Business Officercurrent2023 — presentLausanne, Vaud, Switzerland
- DebiopharmSenior Executive Director, Business Develoment & Commercial2021 — 2023Lausanne, Vaud, Switzerland
- DebiopharmExecutive Director, Head of Marketing, Market Access & Medical Affairs2020 — 2021Lausanne, Vaud, Switzerland
- DebiopharmExecutive Director, Head of Marketing & Market Access2019 — 2020
- DebiopharmHead of Marketing & Market Access2018 — 2020Lausanne, Canton of Vaud, Switzerland
- DebiopharmHead of Marketing2016 — 2018Lausanne, Vaud, Switzerland
- Novo NordiskSenior Global Product Manager, Levemir2013 — 2016Copenhagen Metropolitan Area
- LundbeckGlobal Brand Manager, Azilect2011 — 2013Copenhagen Metropolitan Area
- Brand InstitutePresident, Brand Development - Geneva2009 — 2011
- Brand InstituteDirector, Brand Development2009
- Aardex GroupEMEA Product Manager2007 — 2008
- Aardex GroupSales & Marketing Manager2006 — 2007
- Merck SeronoProject Manager, R&D Signal Transduction2002 — 2005
- Merck SeronoProject Manager, R&D, Screening Department2000 — 2001
Skills & more
Corporate Business DevelopmentOncology, CNS, MetabolismGlobal Commercial StrategyCommercial ManagementProduct MarketingMarket AccessMarket IntelligenceCommercial strategyCustomer centricityCommunicationValue PropositionsBrand Development7
+12 more
Global MarketingMarketing StrategyProduct LaunchesMarketing ManagementPublic RelationsCongressMarket ResearchPharmaceutical IndustryBrand ManagementSegmentationProduct Lifecycle ManagementOnline MarketingLanguages English · French · German
From Nicolas's professional profile.
Colleagues at Debiopharm Innovation Fund
Angela Zubel
Chief Development Officer, Research & Development at Debiopharm Innovation Fund
Bertrand Ducrey
Chief Executive Officer, Debiopharm International & Senior Vice-Chairman, Debiopharm at Debiopharm Innovation Fund
Cedric Odje
Investment Associate at Debiopharm Innovation Fund
Chris Thomas
Director, Investments at Wollemi Capital
David Shin
Investor at Dash Fund
Dawid Książczak
Chief Legal Officer at McWin Capital Partners
Frédéric Lévy
Chief Scientific Officer, Search & Evaluation and Scientific Innovation at Debiopharm Innovation Fund
Kavita Patel
Principal at Muus Climate Partners
Frequently asked questions
- Who is Nicolas Favre?
- Chief Business Officer overseeing Commercial and Business Development. He joined Debiopharm in 2016 and previously held R&D and marketing roles at Merck Serono, Lundbeck and Novo Nordisk. He holds a PhD from the University of Geneva and an MBA.
- Where does Nicolas Favre work?
- Nicolas Favre is Chief Business Officer, Business Development & Commercial at Debiopharm Innovation Fund.
- Where did Nicolas Favre go to school?
- Nicolas Favre studied at OU Business School (MBA, International Marketing); University of Geneva (Ph.D., Biology and Biotechnology); Lycée Collège des Creusets (High School, Economy).
Same school
Also attended University of Geneva74
Massimo PrelzInvestor at DN CapitalChristoph FreiPartner, Head of Energy at Emerald Technology Ventures AgErich SieberFounding General Partner at PeakBridge VCDavid MarcusInvestor at FELIX CAPITALMichelle PiontekImpact & ESG Associate at AENUPatrik BrudererCFO at CV Labs
+ 68 more
Shared employers
Also worked at Debiopharm9
Chris ThomasDirector, Investments at Wollemi CapitalKavita PatelPrincipal at Muus Climate PartnersMarc CikesManaging Director at Debiopharm Innovation FundVincent LepreuxInvestment Principal at Debiopharm Innovation FundTanja DoweManaging Director at Angelini VenturesAngela ZubelChief Development Officer, Research & Development at Debiopharm Innovation Fund
+ 3 more
Also worked at Novo Nordisk31
Jesper GromadaInvestor at Third Rock VenturesDhiren PatelDigital Pharma Advisor at Excelerate Health VenturesBrian DanielsVenture Partner at 5AM VenturesKasim KutayCEO at Novo HoldingsAviva AminovaGeneral Counsel at Omidyar NetworkTaruho KurodaImpact Partner at Fresco Capital
+ 25 more
Also worked at Lundbeck11
Christian Krog-JensenInvestor at Almi InvestJørgen Søberg PetersenSenior Partner at Novo HoldingsCamilla Petrycer HansenPartner at Novo HoldingsJeroen BakkerPartner at Novo HoldingsEric FloydRegulatory Advisor at 2Flo VenturesErik SteffensenExpert advisor at VÅR Ventures
+ 5 more